enVVeno Medical Corporation (NVNO)
| Market Cap | 7.32M -88.0% |
| Revenue (ttm) | n/a |
| Net Income | -18.82M |
| EPS | -30.99 |
| Shares Out | 667.67K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,505 |
| Open | 11.08 |
| Previous Close | 10.90 |
| Day's Range | 9.76 - 11.12 |
| 52-Week Range | 8.67 - 196.70 |
| Beta | 1.08 |
| Analysts | Hold |
| Price Target | 437.50 (+3,891.79%) |
| Earnings Date | May 7, 2026 |
About NVNO
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company’s lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcathe... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for NVNO stock is "Hold" and the 12-month stock price target is $437.5.
News
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment
First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-surgical Replacement Venous Valve IDE approval positions enVVeno to advance what could become the first effective treatment option for the...
enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year
“With a strong balance sheet, significant physician interest in the enVVe valve, and a clearly defined regulatory pathway, we are well positioned to execute the TAVVE study and advance the…
enVVeno Medical sees cash runway into 3Q27
Cash and investments totaled $24.9 million as of March 31, 2026, compared to $28.2 million as of December 31, 2025. The Company believes its current cash and investment resources are…
enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter
The Company anticipates that its cash burn rate may increase to approximately $4 million to $5 million per quarter in 2026 as it prepares for and initiates the TAVVE pivotal…
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System
Company ended the first quarter with approximately $25 million in cash and investments Capital on hand should fund operations through multiple key milestones into Q3 2027 Company recently received FDA...
enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study
enVVeno Medical (NVNO) announced that the U.S. Food and Drug Administration, FDA, has awarded the Company the first-ever IDE approval to proceed with a U.S. pivotal study of a non-surgical…
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve
First-in-Class enVVe system to be evaluated in TAVVE U.S. Pivotal Trial Clinical site activation and patient enrollment expected to commence later this year Large unmet clinical need for approximately...
enVVeno Medical reports FY25 EPS ($33.06) vs. ($44.53) last year
Robert Berman, CEO, stated, “2025 represented a significant inflection point for the Company. Following the FDA’s decision regarding the VenoValve, we made the strategic determination to accelerate de...
enVVeno Medical expects cash burn rate of $4M-$5M per quarter in 2026
The Company expects its cash burn rate to increase modestly in 2026 to approximately $4M to $5M per quarter as it prepares for and initiates the enVVe system pivotal trial.
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System
Company accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation Strong financial position expected to provide an operating ...
NorthStrive Fund II LP Calls on enVVeno Medical to Halt Clinical Spending Plans and Call Special Shareholder Meeting to Vote on Strategic Alternatives
NEWPORT BEACH, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund II”), a subsidiary of NorthStrive Companies Inc., headquartered in Newport Beach, California, and be...
enVVeno Medical regains compliance with Nasdaq minimum bid price rule
enVVeno Medical (NVNO) has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Marketthat the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which r...
enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed Reports Cash and Investments of approximately $28 million as of the Year Ended December 31...
enVVeno Medical trading halted, news pending
19:50 EST enVVeno Medical (NVNO) trading halted, news pending
enVVeno Medical board approves 1-for-35 reverse stock split
enVVeno Medical (NVNO) Corporation announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 35.
enVVeno Medical Announces Reverse Stock Split
IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a r...
enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3rd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation...
enVVeno Medical trading resumes
17:30 EST enVVeno Medical (NVNO) trading resumes
enVVeno Medical receives unfavorable FDA decision for VenoValve
enVVeno Medical (NVNO) announced that it has received an unfavorable decision from the U.S. FDA in response to its supervisory appeal of the not-approvable letter it received on August 19,…
enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve
IRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous dise...
enVVeno Medical trading halted, news pending
16:55 EST enVVeno Medical (NVNO) trading halted, news pending
enVVeno Medical reports Q3 EPS (23c) vs. (35c) last year
The Company ended the quarter with $31M in cash and investments. With the VenoValve commercializations costs and enVVe IDE expenses currently on hold pending resolution with the FDA, this capital…
enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study - Cash burn of $4.2 million in Q3 remains in line wi...
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / September 26, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of ca...
enVVeno Medical to file request for appeal of CDRH non-approvable letter
enVVeno Medical (NVNO) will file a request for supervisory appeal of the not-approvable letter from the Center for Devices and Radiological Health of the U.S. Food & Drug Administration received…